Literature DB >> 16919253

Macroprolactin, big-prolactin and potential effects on the misdiagnosis of hyperprolactinemia using the Beckman Coulter Access Prolactin assay.

M Jane Ellis1, John H Livesey, Steven G Soule.   

Abstract

OBJECTIVE: To examine whether use of the Beckman Coulter Access Prolactin (PRL) assay, which has low reactivity with macro-PRL, obviates the need for screening hyperprolactinemic samples. DESIGN AND METHODS: Samples from 1020 hyperprolactinemic individuals and 401 healthy volunteers were treated with polyethylene glycol (PEG). Macro-PRL was assessed from (1) percent PRL recovery, using cut-off values derived by gel filtration chromatography (GFC) and (2) significant (p<0.05) normalisation of PRL following PEG.
RESULTS: PRL recovery was similar in volunteer and hyperprolactinemic samples (mean+/-SD 101+/-13% and 101+/-19%, respectively). In hyperprolactinemic samples, macro-PRL was identified from PRL recovery in 9.7%, although levels were moderate to high in only 3.9%. The total PRL normalised following PEG in 7.4%. Correlations of PRL recovery with the proportions of macro-, big- and monomeric PRL following GFC (n=30 samples, range of PRL and macro-PRL levels) were -0.89, -0.20 and 0.92, respectively. The big-PRL content was 0-28%. Regression analysis suggested that PEG precipitated both macro-PRL and big-PRL.
CONCLUSIONS: Using the Access assay, macro-PRL can cause apparent hyperprolactinemia and big-PRL may cause misclassification of individuals. Screening using PEG is applicable to assays with low macro-PRL reactivity provided specific reference values are derived.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16919253     DOI: 10.1016/j.clinbiochem.2006.06.003

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  1 in total

1.  Antipsychotics-induced hyperprolactinemia and screening for macroprolactin.

Authors:  Nedjeljka Ruljancic; Ana Bakliza; Sandra Vuk Pisk; Natko Geres; Katarina Matic; Ena Ivezic; Vladimir Grosic; Igor Filipcic
Journal:  Biochem Med (Zagreb)       Date:  2020-12-15       Impact factor: 2.313

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.